Kaicheng Zhu
Senior Scientist, Drug Substance, CMC at Enanta Pharmaceuticals - Watertown Town, MA, US
Kaicheng Zhu's Colleagues at Enanta Pharmaceuticals
Kristin Kleber-sanderson
Executive Director, Head of Clinical Operations
Kaicheng Zhu's Contact Details
617-607-0800
Watertown, Massachusetts, United States
Enanta Pharmaceuticals
Kaicheng Zhu's Company Details
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta's collaboration with AbbVie, have now been approved around the world as part of AbbVie's regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir).Royalties from the AbbVie collaboration are helping to fund Enanta's research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV). Please visit www.enanta.com for more information.